No Data
Amneal Pharmaceuticals Launches Focinvez, Ready-To-Use Injectable Anti-Nausea Agent For Chemotherapy; Second Injectable RTU Product Launched In 2024; Single-Dose Vial Free Of Polysorbate 80, No Reconstitution Required
Amneal Pharmaceuticals Launches Focinvez, Ready-To-Use Injectable Anti-Nausea Agent For Chemotherapy; Second Injectable RTU Product Launched In 2024; Single-Dose Vial Free Of Polysorbate 80, No
Amneal Pharmaceuticals (NASDAQ:AMRX) Doubles Its Share Value and Trade at a Discount
Teva Focus of FTC Investigation Over Inhaler Patents
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments
Amneal Pharmaceuticals (AMRX) said Monday that it has expanded its biosimilar portfolio to eight by adding ADL018, a proposed biosimilar of Novartis' (NVS) Xolair, or omalizumab, to its pipeline. The
Express News | Kashiv Biosciences, LLC - Financial Terms of Transaction Not Disclosed
Express News | Kashiv Biosciences Enters Into Exclusive Licensing Agreement With Amneal for Commercialization of a Proposed Biosimilar to Xolair® (Omalizumab)